Established in December 2016, Wellmarker Bio(WMBIO) is a biotechnology company that develops first-in-class anticancer drugs based on predictive biomarkers. WMBIO conducts genetic analysis on patients who have already been diagnosed with cancer. Unlike genetic testing companies that analyze DNA and diagnose or predict diseases, WMBIO predicts the efficacy of anticancer drug and selects an effective treatment for each individual.